\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesAre you looking for a smarter use of your IP? Do you need help with your IP Strategy? Apply then to the Intellectual Property Booster (IP Booster) services, the specialised professional IP facility for public research organisations looking to realise value from their research results.
To be eligible for support you must be a Public Research Organisation (University, Research Institute or similar), located in one of the EU Member States and with an existing EU PIC (Participant Identification Code) to prove that you have previously been the beneficiary of EU funds for R&D.
Experts will examine your case and guide you towards the best intellectual property strategy, at no cost to you and fully supported by the European Commission.
The Call is open, apply online anytime! Deadline for applications is the 31st of May. For any further information go to the FAQs or Contact IP Booster
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
